1. Home
  2. PH vs SNY Comparison

PH vs SNY Comparison

Compare PH & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PH

Parker-Hannifin Corporation

HOLD

Current Price

$879.47

Market Cap

110.0B

Sector

Industrials

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$44.92

Market Cap

104.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PH
SNY
Founded
1917
1994
Country
United States
France
Employees
57950
74846
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.0B
104.5B
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
PH
SNY
Price
$879.47
$44.92
Analyst Decision
Buy
Buy
Analyst Count
21
5
Target Price
$996.62
$58.00
AVG Volume (30 Days)
700.2K
2.4M
Earning Date
04-30-2026
04-23-2026
Dividend Yield
0.84%
3.47%
EPS Growth
24.18
N/A
EPS
19.95
N/A
Revenue
$14,302,392,000.00
N/A
Revenue This Year
$10.40
$3.49
Revenue Next Year
$7.34
$6.10
P/E Ratio
$43.75
$6.14
Revenue Growth
18.90
N/A
52 Week Low
$652.43
$42.28
52 Week High
$1,034.96
$52.68

Technical Indicators

Market Signals
Indicator
PH
SNY
Relative Strength Index (RSI) 51.38 55.05
Support Level $859.33 $43.32
Resistance Level $908.35 $45.12
Average True Range (ATR) 20.74 0.55
MACD 4.40 0.16
Stochastic Oscillator 77.10 89.70

Price Performance

Historical Comparison
PH
SNY

About PH Parker-Hannifin Corporation

Parker Hannifin started out in 1917 as Parker Appliance, selling pneumatic brakes. Through the acquisition of branded components, the firm has expanded into aerospace engines, agricultural and construction machinery, freight and passenger vehicles, and industrial automation equipment. Within these larger systems, Parker sells a wide array of small, critical pieces such as hydraulic, electromechanical, climate control, and filtration components. Many of its products are designed to work together, resulting in a high rate of cross-selling.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: